Form 4: Vaxart CSO Sells Shares for Tax Obligations

Vaxart's SVP and Chief Scientific Officer, Sean Tucker, reported the sale of 9,265 common shares to cover tax obligations related to vested restricted stock units.

Summary

• Sean Tucker, SVP and Chief Scientific Officer of Vaxart, Inc. (VXRT), reported a transaction on February 2, 2026.
• The transaction involved the disposition of 9,265 shares of Common Stock at a price of $0.6085 per share.
• These shares were withheld by Vaxart, Inc. to satisfy income tax withholding and remittance obligations associated with the net settlement of Restricted Stock Units (RSUs) that vested on February 2, 2026.
• Following this transaction, Sean Tucker directly beneficially owns 731,225 shares of Common Stock.
• Additionally, Sean Tucker indirectly beneficially owns 51,465 shares through a joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares indirectly through a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a routine, non-discretionary transaction related to executive compensation and tax obligations, which does not indicate any positive or negative operational or strategic developments for the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Vaxart, Inc.'s future outlook.

Industry Context

StockSavvy.ai notes that this type of transaction, involving the withholding of shares to cover tax obligations upon the vesting of Restricted Stock Units (RSUs), is a common and routine occurrence for executives in publicly traded companies. It is a non-discretionary event tied to compensation structures and does not typically reflect a change in management's sentiment towards the company's prospects.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's discretionary view of the stock.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations upon RSU vesting. Such transactions are common and do not typically reflect a change in the company's operational performance or future prospects. Therefore, it provides no new information that would warrant a change in an investor's current position, leading to a 'hold' recommendation based solely on this filing.

Keywords

Vaxart, VXRT, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Sean Tucker, Officer